Crinetics Pharmaceuticals (CRNX) Peer Comparison

$84.95

$0.00 (0.00%)

As on 02-Sep-2026 09:30EDT

Market cap

$9,013 Mln

Revenue (TTM)

$42 Mln

P/E Ratio

--

P/B Ratio

7.6

Div. Yield

0 %

Edit

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	9,013	17,274	14,841	14,411	12,927
Revenue ($ Mln)	42	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-501.61	491.50	755.85	860.62	413.60
Net Margin (%)	-1,189.88	17.67	71.69	35.33	24.86
RoE (%)	-45.93	110.09	--	42.98	430.03
Price to Earnings	--	36.40	17.63	18.29	33.40
Price-To-Book	7.56	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	42.16	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	90.36	1,982.07	103.47	85.67	363.07
Gross Profit	6.62	760.62	588.53	2,236.43	1,091.18
Operating Expenses	590.89	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-549.09	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-501.43	598.92	101.11	1,035.47	583.34
Provision for Tax	0.18	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-501.61	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	1,191.96	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	50.01	187.89	384.48	288.55	2,089.43
Current Liabilities	79.92	1,435.43	464.70	361.93	344.44
Total Liabilities	1,135.50	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	77.52	1,006.90	895.24	1,243.41	1,644.38
Current Assets	1,244.36	1,050.29	1,389.84	1,250.82	933.02
Total Assets	1,135.50	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	47.19	120.10	449.89	165.93	2,146.65
Net Current Assets	1,164.45	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-377.92	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	173.91	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	40.61	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-38.50	53.56	-30.01	32.82	15.61
ROE (%)	-45.93	110.09	163.18	42.98	430.03
ROA (%)	-36.35	15.64	31.68	29.32	16.19
EBIT Margin (%)	-1,216.98	21.13	5.73	31.04	36.28
Net Margin (%)	-1,189.88	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	2,928.45	24.67	114.85	9.23	41.15
EBIT Growth (%)	-38.72	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	-35.63	17.50	378.76	42.89	-25.78
EPS Growth (%)	-23.03	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-9.60	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-9.41	36.06	-59.76	15.79	24.99
Price / Book Value	4.41	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-7.37	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.01	0.00	0.05	0.00	1.46
Current Ratio	15.57	0.73	2.99	3.46	2.71
Quick Ratio	15.53	0.73	2.32	3.38	2.31
Interest Coverage	--	--	1.62	--	29.73

Operating Efficiency Ratios

	Crinetics Pharmaceuticals (CRNX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	28.36	15.88	21.25	13.74	27.40
Asset Turnover	0.03	0.89	0.44	0.83	0.65
Receivable days	215.04	50.42	85.52	43.48	98.04
Inventory Days	343.19	--	1,056.70	96.17	190.34
Payable days	4,831.08	6.26	331.01	147.97	18.62
Cash Conversion Cycle	-4,272.85	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly